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Abstract
Materials in particulate form have been the subjects of intensive research in view of their use as drug delivery
systems. While within this application there are still issues to be addressed, these systems are now being
regarded as having a great potential for tissue engineering applications. Bone repair is a very demanding task,
due to the specific characteristics of skeletal tissues, and the design of scaffolds for bone tissue engineering
presents several difficulties. Materials in particulate form are now seen as a means of achieving higher control
over parameters such as porosity, pore size, surface area and the mechanical properties of the scaffold. These
materials also have the potential to incorporate biologically active molecules for release and to serve as carriers
for cells. It is believed that the combination of these features would create a more efficient approach towards
regeneration. This review focuses on the application of materials in particulate form for bone tissue
engineering. A brief overview of bone biology and the healing process is also provided in order to place the
application in its broader context. An original compilation of molecules with a documented role in bone tissue
biology is listed, as they have the potential to be used in bone tissue engineering strategies. To sum up this
review, examples of works addressing the above aspects are presented.
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Abstract
Materials in particulate form have been the subjects of intensive research in view of their use as
drug delivery systems. While within this application there are still issues to be addressed, these
systems are now being regarded as having a great potential for tissue engineering applications.
Bone repair is a very demanding task, due to the specific characteristics of skeletal tissues, and the
design of scaffolds for bone tissue engineering presents several difficulties. Materials in particulate
form are now seen as a means of achieving higher control over parameters such as porosity, pore
size, surface area and the mechanical properties of the scaffold. These materials also have the
potential to incorporate biologically active molecules for release and to serve as carriers for cells. It
is believed that the combination of these features would create a more efficient approach towards
regeneration. This review focuses on the application of materials in particulate form for bone tissue
engineering. A brief overview of bone biology and the healing process is also provided in order to
place the application in its broader context. An original compilation of molecules with a documented
role in bone tissue biology is listed, as they have the potential to be used in bone tissue engineering
strategies. To sum up this review, examples of works addressing the above aspects are presented.
Copyright  2007 John Wiley & Sons, Ltd.
Received 13 December 2006; Accepted 20 December 2006
Keywords microparticles; nanoparticles; growth factors; bone tissue engineering; scaffolds; cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Contents
1. Materials in particulate form and bone tissue
engineering (TE)
2. Requirements for an effective bone TE strategy
3. Materials in particulate form: towards bone TE
4. Conclusions
References
1. Materials in particulate form and
bone tissue engineering (TE)
Regarding materials for use in bone TE, several
approaches have been shown to be effective in stimulating
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bone regeneration, and ceramics especially excel in this
regard(Degroot, 1993; Hench, 1998; Ducheyne and Qiu,
1999). Notwithstanding the stimulatory effect of bioactive
ceramics on bone tissue formation, there is a continuous
need to explore avenues in which materials, cells and bio-
logically active molecules are combined. This is critical,
since cells and growth factors are the two key elements
when discussing bone biology/healing, their interaction
being fundamental for an effective regeneration process.
Although continuous progress is being made in under-
standing osseous healing process, these new insights have
not readily found their way into effective TE approaches.
The combination of materials, cells and growth factors
seems to be the recipe for a truly effective bone TE strat-
egy. Therefore, the present review focuses on the role that
particle-based systems can play in bone TE, emphasizing
the combination of materials with cells and their role as
carriers for biologically active molecules.
Copyright  2007 John Wiley & Sons, Ltd.
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2. Requirements for an effective bone
TE strategy
The skeletal system has been described as a dynamic,
mineralized, vascular tree that serves as a metabolic
reservoir of calcium as well as a structural scaffold for
neurovascular distribution and muscular function(Roberts
and Hartsfield, 2004). Important properties that are part
of the skeletal system (Canalis, 1983; Hauschka, 1990;
Tenembaum, 1990; Yaszemski et al., 1996; Roberts and
Hartsfield, 2004) are:
• It is the reservoir of calcium in the body, containing
99% of the body’s calcium.
• Its homeostasis is regulated to a large degree by
systemic influences expressed through the endocrine
system, but also controlled at the local level.
• Its structural function derives from its nature as
mineralized tissue.
• It is an anisotropic material (the mechanical properties
vary according to the direction).
• Its physiological efficiency is evidenced by maximal
strength with minimal mass.
• It has a relative high turnover (remodelling) rate in
young individuals.
The ultimate goal of bone TE is to recapitulate the
structure and function of the native tissue it is designed to
replace (Schneider et al., 2003). Therefore, the following
principles apply to scaffolds for bone tissue engineering:
1. Bone TE scaffolds require not only a material
with adequate composition, but also mechanical
stability, precise shapes and tailored pore distribution
(Gross and Rodriguez-Lorenzo, 2004; Rodr´ıguez-
Lorenzo and Ferreira, 2004). Osseous tissue is
an exquisitely structured composite material: it is
composed of organic and inorganic components
and also contains water. The inorganic component
is apatitic calcium phosphate, which comprises
60–70% of the bone dry weight. The organic
component contains materials such as collagen,
extracellular matrix proteins (osteocalcin, osteonectin,
bone sialoprotein), tissue-specific cells and water (Jain
and Panchagnula, 2000). Having this in mind is crucial
for the design and fabrication of an adequate scaffold.
The adult skeleton consists of cortical (or compact)
and trabecular (or cancellous, spongy) bone, which
are present in various ratios and geometries to form
the individual bones of the body (Buckwalter et al.,
1996; Mundy, 2000; Davies, 2003). Both cortical
and trabecular bone tissue types are essential for the
ability of skeleton to provide structural support that
can simultaneously withstanding torsion and bending.
A minimum pore size is required for tissue growth,
interconnectivity for access to nutrients and transport
of waste products, pore shape and roughness for better
cell spreading and pore throat size for passage of
tissue throughout the scaffold (Ranucci and Moghe,
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1999; Zeltinger et al., 2001; Gross and Rodriguez-
Lorenzo, 2004). The lack of adequate porosity can
lead to failure, as inner areas of the scaffold will lack
adequate nutrient and oxaemic conditions to allow
cells to populate those areas (Gross and Rodriguez-
Lorenzo, 2004).
2. The material should act as a permissive environment
into which bone cells would be enticed to migrate
and begin the process of depositing bone matrix in
the carrier template (Li and Wozney, 2001). Bone,
being a mineralized tissue that is incapable of internal
expansion or contraction, can only be remodelled
along the surface via anabolic and catabolic modelling
(Roberts et al., 2004). Bone is resorbed by osteoclasts
and formed by osteoblasts, and the coupling of these
two processes underlies bone remodelling. Figure 1
depicts the bone healing process, which the repair
using scaffold materials attempts to mimic. Briefly,
upon fracture and formation of a blood clot, the
fibroblast layer of the periosteum begins a period of
active division in order to generate enough cells to
close the gap at the surface. In the central zone of the
bone, haematopoietic precursors in the bone marrow
differentiate into osteoclasts that start the process of
resorbing the end bone of the defect, and mesenchymal
cells within the bone marrow are stimulated to migrate
to the healing site. These cells originate chondrogenic
cells that produce an intermediate cartilaginous matrix
that mineralizes. This cartilaginous phase is then
replaced by new bone synthesized by osteoblasts.
This newly formed bone is the so-called ‘woven
bone’, which possesses an unorganized structure
and still needs to be remodelled by the normal
osteoclast–osteoblast process (Davies, 2003; this
scheme does not incorporate the vascularization
process). To be successful, a scaffold material must
be capable of allowing a similar process to occur.
Ideally, the scaffold would degrade at a similar rate to
that at which the tissue is healing, and the new tissue
would fully replace the space once occupied by the
scaffold.
3. A system designed for bone repair would ideally com-
bine osteoconductive and osteoinductive properties,
in a way that new bone formation can be enhanced
through an adequately shaped three-dimensional (3D)
scaffold (osteoconduction) and by a biological stimulus
(osteoinduction) (Luginbuehl et al., 2004). Ceramic
materials, due to their inorganic nature and ionic com-
position, are adequate for bone applications. Examples
of ceramic materials are calcium phosphates, such
as hydroxyapatite, tricalcium phosphate and bioactive
glasses, known for their ability to bond to and stimu-
late bone regeneration (Ripamonti, 1991, 1996; Klein
et al., 1994; Ducheyne and Qiu, 1999; Yuan et al.,
2001). From these, bioactive glass has been shown to
stimulate osteogenesis (Jun Yao, 2005; Radin, 2005)
via surface-mediated and solution-mediated mecha-
nisms (Radin et al., 1997). Other materials besides
bioactive glasses have been extensively used, such as
Copyright  2007 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2007; 1: 000–000.
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Figure 1. Healing process• of bone, depicted in a simplified diagram. After the defect and formation of a blood clot, haematopoietic
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precursors (H) in the bone marrow differentiate into osteoclasts (OC), which start the process of resorbing the end bone of the
defect. Mesenchymal cells (MSCs) within the bone marrow are stimulated to migrate to the healing site. These cells originate
chondrogenic cells (CB), which produce an intermediate cartilaginous matrix that progressively mineralizes. This cartilaginous
phase is then replaced by new bone synthesized by osteoblasts (OB). Not depicted is the role of vascularization. Based on Simmons
and Grynpas (1990) and Rydziel et al. (1994)
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β-tricalcium phosphate (TCP) (Zerbo et al., 2005) and
hydroxyapatite (Paul and Sharma, 1999; Sari et al.,
2003), but there are also some reports of the use
of composite materials (ceramic–polymer) (Shikinami
and Okuno, 1999). Composite ceramic–polymer mate-
rials have the advantages of combining bioactivity,
ability of adequate control of the scaffold degradation
rate, and enhancement of the mechanical properties
and structural integrity of scaffolds (Day et al., 2004).
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4. Some biologically active molecules act locally and
therefore must be delivered directly to the site of
regeneration via a carrier matrix (Li and Wozney,
2001). The system should be able not only to
provide structural support but also to serve as carrier
for biologically active agents that can enhance the
regenerating potential of the system. These agents can
be of different natures, as listed in Table 1. Since the
identification of bone morphogenetic proteins (BMPs)
Copyright  2007 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2007; 1: 000–000.
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by Urist (1965), several other growth factors, as well
as hormones and other biologically active agents, have
been identified as acting in bone, and have recently
been of interest for bone tissue engineering strategies.
Two groups of molecules (growth factors and steroids)
with well-documented effects over bone, and considered
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relevant to the field of bone tissue engineering, are
described below.
2.1. Growth factors
Among all available growth factors, PDGF, IGF, VEGF,
TGFβ and BMPs appear to have the closest association
Table 1. Some molecules and trace elements with a brief description of their role/effect on bone, compiled in the scope of this review
Molecule Role/effect on bone tissue Reference
Bone morphogenetic proteins (BMPs):
BMP-2, BMP-4, BMP-3, BMP-5, BMP-6,
BMP-7(OP-1)
Expressed in bone generation, regeneration,
modelling and remodelling. Stimulate
differentiation of osteoblasts and inhibit
differentiation of muscle cells. Induce
endochondral bone formation in ectopic sites
(Urist, 1965, 1997; Urist et al., 1979; Cheifetz
et al., 1996; Yeh et al., 1997; Wada et al., 1998;
Wozney and Rosen, 1998; Chen et al., 2001;
Reddi, 2001)
Epidermal growth factor (EGF) Stimulates chondrocyte proliferation while
decreasing the ability of cells to synthesize
matrix components
(Caplan and Boyan, 1994)
Basic fibroblast growth factor (bFGF) Mitogenic effects on cells from the
mesenchymal lineage. Promotes proliferation
and inhibits differentiation. Involved in fracture
repair
(Pitaru et al., 1993; Caplan and Boyan, 1994;
Lockin et al., 1999; Mundy, 2000)
Insulin-like growth factor (IGF) Enhances osteoblast activity and chemotaxis,
type I collagen production, decreases collagen
degradation, stimulates growth in various cell
types and blocks apoptosis. Induces bone
formation. Enhances VEGF expression in
osteoblasts
(Goad et al., 1996; Mundy, 2000; Meinel et al.,
2001)
Platelet-derived growth factor (PDGF) Potent mitogen and chemotactic factor for cells
of mesenchymal origin. Anabolic action on
bone formation in vivo
(Kim and Valentini, 1997; Hsieh and Graves,
1998; Park et al., 2000)
Transforming growth factor-β (TGFβ) Mitogenic and chemotactic effects; increase in
collagen and extracellular matrix synthesis. New
bone formation. Involved in fracture repair.
May promote osteoclast apoptosis.
Overexpression leads to osteoclast-mediated
resorption. Potent inhibitor of terminal
differentiation of epiphyseal plate chondrocytes
(Marcelli et al., 1990; Centrella et al., 1994;
Erlebacher and Derynck, 1996; Hugues et al.,
1996; Kim and Valentini, 1997; Ripamonti
et al., 1997; Duneas et al., 1998; Lockin et al.,
1999; McCarthy et al., 2000; Mundy, 2000;
Schmidmaier et al., 2003; Kahai et al., 2004;
Li et al., 2005)
Hepatocyte growth factor (HGF) Contributes to fracture repair by upregulating
the expression of BMP receptors
(Imai et al., 2005)
Vascular endothelial growth factor (VEGF) Induces vascularization (Mohle et al., 1996; Vu and Werb, 1998;
Asahara et al., 1999; Gerber et al., 1999)
Calcitonin Secreted by the thyroid gland. Controls the
levels of calcium and phosphorous in the blood.
When administered, inhibits bone resorption by
decreasing the number of osteoclasts and their
resorptive activities. Effectively inhibits the
manifestations of metabolic bone disorders,
such as Paget’s disease and osteoporosis by
frequent and relatively high dosage
(Overgaard and Christiansen, 1991; Lee and
Sinko, 2000; Patton, 2000; Inzerillo et al., 2002)
Melatonin Increased proliferation of osteoblastic cells and
increased procollagen type I c-peptide
production. Augmented gene expression of
sialoprotein and other bone marker proteins,
e.g. alkaline phosphatase and osteocalcin in
bone cells. Modifies bone remodelling after
ovariectomy in close relation with estradiol
(Roth et al., 1999; Ladizesky et al., 2001)
Parathyroid hormone (PTH) In low dose causes increase in bone density and
cancellous/trabecular bone volume without
impairing normal bone architecture and has a
direct effect on recruitment/proliferation of
osteoblasts
(Stewart, 1996; Morley et al., 1997; Watson
et al., 1998; Mohan et al., 2000; Patton, 2000;
Rattanakul et al., 2003; Schneider et al., 2003)
Thyroxin Thyroid hormone which stimulates osteoclastic
bone resorption
(Buckwalter et al., 1996)
Cortisol Influences PTH-responsiveness of bone.
Inhibitor of the stimulatory effect of IGF-I
(Ng and Heersche, 1978; Tam et al., 1979;
Chyun et al., 1984)
Interleukin-6 (IL-6) Stimulates the differentiation of osteoclasts
from haematopoietic precursors
(Ishimi et al., 1990; Migliaccio et al., 1991)
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Table 1. (Continued)
Molecule Role/effect on bone tissue Reference
Interleukin-1 (IL-1) Stimulates the effect of IL-6. Most potent
inducer of bone resorption
(Gowen et al., 1985a, 1985b; Hoffmann et al.,
1987; Hauschka, 1990)
Tumour necrosis factor (TNF) Stimulates the effect of IL-6. Stimulates bone
resorption and suppresses its formation
(Bertolini et al., 1986; Bockman et al., 1987;
Canalis, 1987; Stashenko et al., 1987)
Prostaglandin E2 (pE2) Potentates the effect of IGF-I.
Concentration-dependent actions (regulation of
the expression of other molecules). Increases
expression of BMP-7 (OP-1)
(Chyun and Raisz, 1982, 1984; Dewhirst et al.,
1987; Paralkar et al., 2002)
Interferon-β (IFN-β) Suppresses osteoclastogenesis and bone
resorption
(Nakamura et al., 2005)
Interferon-γ (IFN-γ ) Suppresses bone resorption induced by IL-1 (Nakamura et al., 2005)
Bi-phosphonates Etidronate Considered stable analogues of pyrophosphate, (Ezra and Golomb, 2000; Patton, 2000;
Clodronate a physiological regulator of calcification and Roschger et al., 2001)
Pamidronate bone resorption. Decrease bone
Alendronate resorption/increase bone mass
Ibandronate
Risedronate
Zolendronate
Tiludronate
YH 529
Icadronate
Olpadronate
Neridronate
EB-1053
TRK-300 Decreases the level of tumour necrosis factor
alpha (TNFα) in the bone marrow of rats with
adjuvant arthritis
(Iwase et al., 2002)
Ipriflavone (Isoflavone) Synthetic flavonoid derivative that improves
osteoblast cell activity inhibiting bone
resorption
(Brandi, 1993; Civitelli, 1997; Perugini et al.,
2003)
Anthraquinones Anti-inflammatory and anti-osteoclastic activity (Savarino et al., 2005)
Vitamin D and analogueues Regulates osteoblast differentiation by either
activating or repressing transcription of
numerous bone phenotypic genes. Increases
TGFβ levels
(Brandi, 1993; Drissi et al., 2002)
TAK-778 [(2R,4S)-(−)-N-(4-
diethoxyphosphorylmethyl-phenyl)-1,2,4,5-
tetrahydro-4-methyl-7,8-methylenedioxy-5-
oxo-3-benzothiepin-2-carboxamide]
TAK-778, a benzothiepin derivative, increased
cellular alkaline phosphatase activity, an index
of bone formation, in a culture of rat bone
marrow stromal cells, and enhanced the action
of BMP in mouse osteoblastic cell line MC3T3-E1
(Hoshino et al., 2000)
TP508 (thrombin peptide) Activates angiogenesis-related genes during
femoral fracture healing. Regulates BMP-2 and
-7 expression by human osteoblasts. Enhances
bone formation
(Bi et al., 2001; Wang et al., 2001, 2002;
Li et al., 2003; Sheller et al., 2004)
Indomethacin Found to inhibit osteoclasts and to decrease the
resorptive area
(Adachi et al., 1991)
Corticosteroids (glucocorticoids) Excess generally associated with net bone loss,
due to decrease in bone formation and increase
in bone resorption
(Heersche and Aubin, 1990)
Statins Generally used for inhibiting HMG Co-A
reductase (rate-limiting step in cholesterol
synthesis).
(Mundy, 2000)
Enhance transcription of BMP-2 in bone cells
Oestrogen/testosterone Deficiency results in high turnover of bone
remodelling in which the accelerated bone
resorption and formation simultaneously occur,
but with resorption exceeding formation.
Protective effect on bone tissue mass
(Caplan and Boyan, 1994; Kaye et al., 1997;
Ladizesky et al., 2001; Sikavitsas et al., 2001)
Trace elements
Fluoride Anabolic effects on bone, but has a narrow
toxic-therapeutic window
(Simmons and Grynpas, 1990; Brandi, 1993;
Mundy, 2000)
Strontium Potential increase in bone mass
Aluminium Causes mineralization deficit by inhibiting
hydroxyapatite crystal formation. Interferes
locally with osteoblast maturation
Boron Tin Deficiency causes osteopenia. Intervene in
magnesium metabolism. Interact with calcium
and other ions
Zinc Significant for coupling–uncoupling of the
remodelling process
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with bone regeneration. PDGF plays an important role
in inducing the proliferation of undifferentiated cells in
mesenchymal tissues. It can enhance bone regeneration
in conjunction with other growth factors, viz. IGF, TGFβ
or BMP, but is unlikely to provide entirely osteogenic
properties itself (Schliephake, 2002). IGFs have an
important role in general growth and maintenance of
the body skeleton, and appear to integrate and extend the
effects of both BMPs and TGFβs (McCarthy et al., 2000).
Equally important is VEGF, which couples ossification
and angiogenesis during bone formation (Gerber et al.,
1999; Street et al., 2002). BMPs are thought to have their
major effects on early precursor bone cell replication and
osteoblast commitment. In contrast, TGFβs are thought
to be the most potent inducers of committed bone cell
replication and osteoblast matrix production (McCarthy
et al., 2000).
2.1.1. Bone morphogenetic proteins
Growing interest in the clinical use of BMPs as means
of promoting bone formation has led to extensive
studies on this group of growth factors. In brief,
BMPs are hydrophobic, low molecular weight, dimeric
molecules with two polypeptide chains held together
by a single disulphide bond (Ozkaynak et al., 1990;
Wang et al., 1990; Reddi, 2001). The name stems from
the demonstration of a hydrophobic non-collagenous
glycoprotein that induced mesenchymal-type cells to
differentiate into a spherical ossicle with a medulla
containing haematopoietic bone marrow (Urist et al.,
1979).
This family of secreted growth factors forms a subgroup
of molecules within the transforming growth factor-
β (TGFβ) superfamily. The history of BMP evolved
from observations of allogenic bone matrix-induced
cartilage and bone development in mammalian species.
In embryogenesis, BMPs appear to be omnipresent, being
observed in nearly all developing visceral and somatic
organs (Urist, 1997). At least two distinct pathways
mediate BMP signalling: the •Smad pathway and theAQ1
mitogen-activated protein kinase (MAPK) pathway (Yoon
and Lyons, 2004).
2.1.2. Platelet-derived growth factor
Effects by platelet-derived growth factors (PDGFs) are
generally limited to situations associated with inflamma-
tion and repair (McCarthy et al., 2000). However, PDGFs
have been shown to be involved in the chemotaxis of
osteoblast precursors to the site of bone regeneration
(Mundy et al., 1982; Hsieh and Graves, 1998). In vitro,
they have been shown to stimulate migration and to
increase the proliferation rate of osteoblasts, reducing
alkaline phosphatase activity and inhibiting bone matrix
formation (Centrella et al., 1989, 1991; Hock and Canalis,
1994).
There are three isoforms, characterized by the com-
bination of A- and B-chains, featuring two homodimeric
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(PDGF-AA and PDGF-BB) and one heterodimeric isoform
(PDGF-AB) (Hock and Canalis, 1994; Rydziel et al.,
1994). PDGF-BB and PDGF-AB are systemically circulat-
ing isoforms contained in α-granules of platelets, whence
they are released after adhesion of platelets to injured
sites of vessel walls, whereas PDGF-AA is secreted by
unstimulated cells of the osteoblastic lineage (Canalis
et al., 1992; Rydziel et al., 1994).
The biochemical effects of the different isoforms appear
to be graded according to their binding characteristics
to the surface receptors. In osteoblast-enriched environ-
ments, receptors that favour binding of PDGF-BB chains
preferably mediate these effects (Centrella et al., 1991).
PDGF may thereby contribute to recruitment of bone
cells during remodelling and repair, as it is deposited
in bone matrix, from where it is released during matrix
degradation (Fuiji et al., 1999).
The effectiveness of PDGFs on osteoblasts is rapidly
modulated by inflammatory cytokines, causing changes
in specific PDGF receptors (McCarthy et al., 2000). The
activated receptors lead to activation of the MAPK
cascade, resulting in the transcription of important genes
related to bone formation (Schlessinger, 1993).
2.2. Corticosteroids
Corticosteroids are a class of steroid hormones that are
produced in the adrenal cortex. They are involved in
a wide range of physiological systems, such as stress
response, immune response and regulation of inflamma-
tion, carbohydrate metabolism, protein catabolism, blood
electrolyte levels, and behaviour. This class of molecules
is often used as part of the treatment for a number of
different diseases, such as severe allergies or skin prob-
lems, asthma or arthritis. Within corticosteroids there
are mineralocorticoids and glucocorticoids, and a brief
description of the latter follows.
2.2.1. Glucocorticoids
Glucocorticoids such as cortisol control carbohydrate, fat
and protein metabolism and are anti-inflammatory by
preventing phospholipid release, decreasing eosinophil
action and a number of other mechanisms.
Physiological amounts of glucocorticoid tend to have
permissive effects on •osteoblasts45. However, either AQ2
when endogenously in excess or when administered
exogenously, glucocorticoids lead to a dramatic decrease
in bone mineral density. Whereas chronic glucocorti-
coid exposure suppresses bone formation and disrupts
resorption and the bone remodelling cycle, major detri-
mental effects on the skeleton occur from a decrease
in osteoblast replication, bone matrix protein synthesis,
marked decrease in osteoblast gene transcription and
skeletal tissue loss (McCarthy et al., 2000; Kumar, 2001).
Pharmacological doses of the glucocorticoids cortisol
and dexamethasone directly lower basal IGF-I expression
(McCarthy et al., 1990), and in vitro studies have revealed
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that high excess glucocorticoid suppresses the expres-
sion of IGF-I and the type TGFβ receptor (TGFβRI•) byAQ3
osteoblasts, consistent with decreases in specific aspects
of osteoblast function (McCarthy et al., 2000).
Dexamethasone is a synthetic member of the glucocor-
ticoid class of hormones. It acts as an anti-inflammatory
and immunosuppressant, with potency about 40 times
that of hydrocortisone (Barnes and Adcock, 1993; Almawi
et al., 1998; Saklatvala, 2002). In vitro, dexamethasone
has been employed as a differentiation agent for bone
marrow cells to progress into the osteoblastic lineage
(Maniatopoulos et al., 1988). Within this last role, strate-
gies employing the incorporation of dexamethasone in
polymeric materials to be used as carriers for the differ-
entiation of cells into the osteoblastic lineage have been
described in the literature (Silva et al., 2005), which con-
fers on dexamethasone a highlighted role in bone TE
approaches.
3. Materials in particulate form:
towards bone TE
In recent years there has been interest on the fabrication
of 3D systems using a microsphere-based approach
for a TE scaffold possessing a porous interconnected
structure (Devin et al., 1996; Botchwey et al., 2001),
with the incorporation of ceramics to control the
mechanical properties of the sintered scaffold (Borden
et al., 2002a, 2002b). This is an extremely interesting
strategy, as it provides a potential to overcome normally
encountered problems associated with porosity of the
scaffold. Additionally, with particle-based systems shaped
as scaffolds, the surface area for more chemical and
biological reactions to take place is greatly increased
(Mushipe et al., 2002).
The formation of 3D scaffolds from materials in
particulate form creates the potential for these systems
to be used either in an acellular strategy (implanting
of the scaffold and colonization of it by surrounding
cells) or combining it with cells in vitro, creating a
hybrid cell–material construct. Simultaneously, these
scaffolds can also be used as delivery systems, having a
multifunctional purpose – support and release of bioactive
agents – enhancing the regenerative potential of the
system.
3.1. Microparticle-based systems in 3D scaffolds
Materials in particulate form in bone applications have
as first examples the filling applications of ceramic
particulate materials. Schepers et al. (1991, 1993) and
Schepers and Ducheyne (1997) described the ability of
bioactive glass particulates within a narrow size range to
act as fillers for bone lesions. When implanted in the jaws
of beagle dogs, the particulates were capable of acting
as nucleation sites for further bone repair, eliciting bone
tissue formation throughout 5 mm defects in the beagle
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
mandible as soon as 1 month after implantation (Schepers
et al., 1991, 1993; Schepers and Ducheyne, 1997).
However, as cells in the body grow in three dimensions,
anchored onto a network of extracellular matrix, a scaffold
is needed to recreate the 3D environment (Yu et al.,
2004). Classical examples of materials shaped for bone
tissue engineering involve 3D porous structures obtained
by conventional processing methods that, in an conductive
approach, are implanted at an injury site and allow
progenitor cells from the surrounding tissue to populate
the wound site (Nof and Shea, 2002).
Given that porosity, pore size and interconnectivity are
very important parameters for the success of a bone
TE system, the strategy based on µm-sized particles
for fabrication of 3D scaffolds seems to be promising,
as a means of achieving more control over the above
parameters. So far, the following strategies have been
studied to fabricate scaffolds from materials in particulate
form:
• Combining particulate materials with gels/glues. In
bone reconstruction, the combination of particulate
ceramics and fibrin glue may result in the synergy
of their properties, as the physical properties of the
composite can be enhanced. The initial stability of
the ceramic–fibrin glue composite may be achieved
through its adaptation and adhesion to the walls of
the bone defect. The biological properties might also
be enhanced due to fibrin, which acts positively on
angiogenesis, cell attachment and proliferation (Le
Nihouannen et al., 2006). The problem associated with
this type of approach is the lack of porosity. Although
cell adhesion would be greatly enhanced by fibrin glue,
the penetration of cells into the interior of the scaffold
is limited by this lack of porosity.
• Dispersing microparticles within ceramic phases for
posterior creation of porosity. Other strategies have
focused on dispersing microparticles within ceramic
phases, where the rationale for this is that the
microspheres will initially stabilize the graft but can
then degrade to leave behind macropores on the
calcium phosphate cement (CPC) for colonization by
osteoblasts. The CPC matrix could then be resorbed
and replaced with new bone (Simon et al., 2002).
This relies on the degradation of the microparticles,
which depends greatly on the material from which the
microparticles are produced, as well as the implant
site. It creates difficulties for osteblast colonization,
particularly to the inner areas of the scaffold, as the
particles might not degrade as fast as necessary to
avoid the failure of the implant. An interesting way of
overcoming these problems might be the incorporation,
within the matrix of microparticles, of enzymes that
can degrade them and thus speed the process of pore
formation, as described by other researchers (Martins
et al., 2004a, 2004b).
• Incorporating polymer microspheres with polymeric
scaffolds. This approach permits the incorporation
of growth factor-containing polymeric microspheres
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during polymer scaffold fabrication (Meese et al.,
2002). The basic principle of this approach is to
transiently protect the microspheres with a water-
soluble coating that resists the organic solvents
used during scaffold fabrication. The incorporation of
microspheres in scaffolds not only allows the protection
of the growth factor during fabrication of the scaffold,
but also allows the scaffold to provide both structural
support and controlled release properties.
• Sintering microspheres together. The previous app-
roaches have paved the way for the use of microparticles
as scaffolds. Microparticles can be used to form 3D
scaffolds by utilizing the heating energy of a laser
beam to sinter polymer microparticles, allowing the
fabrication of 3D scaffolds with a controlled architecture
and a fully interconnected network (Botchwey et al.,
2001; Ciardelli et al., 2004; Yao et al., 2005). By
modifying processing parameters, such as sphere
diameter and heating time, it is possible to tune the
properties of the scaffold. It was found that increased
microsphere diameter resulted in decreased modulus,
as well as a positive correlation between sphere
diameter and pore diameter (Borden et al., 2003).
Heating time modifications showed that compressive
modulus was dependent on the period of heating,
with longer heating times resulting in higher moduli,
while the heating time did not affect the pore structure
(Borden et al., 2003). These scaffolds can be further
tested, not only in static but also in dynamic conditions,
such as those found in bioreactors.
3.2. Microparticle-based systems in hybrid
cell–material constructs
Materials in particulate form have been used for
combination with cells in two main approaches: the
encapsulation of cells for site-specific delivery, or the
combination of scaffolds and cells in hybrid constructs in
in vitro approaches.
Examples of the former include the encapsulation of
specific quantities of cells together with bioactive glass
into alginate beads (Keshaw et al., 2005). Alginate beads
have been extensively used for the encapsulation of
several cell types (Shoichet et al., 1996; Chandy et al.,
1999; Papas et al., 1999; Lu et al., 2000; Read et al.,
2001; Orive et al., 2003; Zimmermann et al., 2005).
The study in question (Keshaw et al., 2005) showed
that the encapsulated cells remained viable and secreted
significantly more VEGF compared with beads containing
no glass particles. This demonstrates that cells can be
encapsulated for delivery and with the appropriate stimuli
(here conferred by bioactive glass) can serve at the same
time as the delivery vehicles for growth factors. With
further optimization, this technique offers a novel delivery
device for stimulating therapeutic angiogenesis, the lack
of which in bone TE has been regarded a contributory
factor for implant failure (Keshaw et al., 2005).
Temporary encapsulation of cells in microparticles may
protect the cells from short-term environmental effects,
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such as those associated with the delivery to the regen-
eration site. To overcome certain problems encountered
in cell therapy, particularly cell survival and lack of cell
differentiation and integration in the host tissue, Tatard
et al. (2005) developed pharmacologically active micro-
carriers (PAM). These biodegradable particles, made with
poly(D,L-lactic-coglycolic acid) (PLGA) and coated with
adhesion molecules, may serve as a support for cell culture
and may be used as cell carriers, presenting a controlled
delivery of active protein (Tatard et al., 2005). They can
thus support the survival and differentiation of the trans-
ported cells as well as their microenvironment (Tatard
et al., 2005).
However, for bone applications, approaches that use
the materials in particulate form, not only to deliver and
temporarily protect the cells, seem to be more adequate, as
they can also provide structural support while necessary.
Ceramic materials, such as hydroxyapatite particles (both
dense and microporous), have been evaluated both
in vitro and in vivo as carriers in an injectable tissue-
engineered bone filler (Fischer et al., 2003). After seeding
and culturing goat mesenchymal progenitor cells on the
different types of particles, several layers of cells and
ECM held the particles together in a 3D arrangement.
The subcutaneous implantation of the constructs (with
individual particle size of 212–300 µm) in nude mice
revealed abundant bone formation by 4 weeks (Fischer
et al., 2003).
An important issue in bone TE concerns the possibility
of limited tissue ingrowth in TE constructs because
of insufficient nutrient transport (Yu et al., 2004). To
overcome such limitations, Ducheyne and co-workers
(Qiu et al., 1998, 1999, 2000, 2001) envisioned a strategy
using the HARV bioreactor and microcarriers to engineer
constructs that could be used for bone TE purposes.
In a first approach, the authors used bioactive glass,
Cytodex-3 beads and rat stromal cells for assessing
the feasibility of culture using a HARV bioreactor (Qiu
et al., 1998). It was observed that 3D multicellular
aggregates consisting of multiple cell-covered Cytodex-3
microcarriers bridged together, as well as mineralization
taking place, and the expressions of alkaline phosphatase
activity, collagen type I, and osteopontin were shown (Qiu
et al., 1998). The authors further developed bioactive
ceramic hollow microspheres with an apparent density in
the range 0.81.0 g/cm3 as microcarriers for 3D bone
tissue formation in rotating-wall vessels (RWV). Cell
culture studies using rat bone marrow stromal cells and
osteosarcoma cells showed that the cells attached to and
formed 3D aggregates with the hollow microspheres in a
RWV. Extracellular matrix was observed in the aggregates
(Qiu et al., 1999). Similarly, polymer–glass–ceramic
composite microspheres, composed of modified bioactive
glass (MBG) powders in a polylactic acid (PLA) matrix,
were shown to possess adequate properties for bone TE
purposes (Qiu et al., 2000). Yu et al. (2004) have used a
similar approach, but mixing lighter-than-water (density
<1 g/ml) and heavier-than-water (density >1 g/ml)
microspheres of 85 : 15 poly(lactide-co-glycolide) and
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constructing the scaffold prior to cell seeding by sintering
of the microspheres. When rat primary calvarial cells were
cultured on the scaffolds in bioreactors for 7 days, the 3D
dynamic flow environment affected bone cell distribution
and enhanced cell phenotypic expression and mineralized
matrix synthesis within the tissue-engineered constructs,
compared with static conditions (Yu et al., 2004). It has
been found that with the stress stimulation inside the
fluid in the RWV, the active expression of ALP can be
increased and the formation of mineralized nodules can
be accelerated (Song et al., 2004). These studies show
that 3D fabrication of engineered bone seems an adequate
strategy.
3.3. Microparticle-based systems as scaffolds
and carriers for bioactive molecules
By far the major field of application of particle-based
systems (in both the micro- and the nano-range) is as
drug delivery systems, as described in detail in the first
part of this review (Silva et al., 2006). Their small size
but high surface area renders them attractive for a whole
range of applications, including bone TE.
In bone tissue regeneration, the use of conductive
scaffolds in combination with the delivery of bioactive
factors to direct cellular responses and subsequent
tissue formation is a very attractive strategy to enhance
regeneration (Nof and Shea, 2002), but parameters such
as instability and rapid clearance (short plasma half-life)
of these molecules after in vivo bolus delivery have led
to the need for advanced vehicles for localized release
(Baldwin and Saltzman, 1998; Li and Wozney, 2001;
Norton et al., 2005). The physicochemical properties
of many peptides and proteins make their entrapment
difficult, because inactivation is possible during their
incorporation (Couvreur and Puisieux, 1993). Stability,
solubility and sensitivity to light, heat, moisture and pH,
intermolecular interactions following co-precipitation or
gelling, and adsorption and interaction with excipients
are parameters that should be investigated in order to
succeed in producing a stable association of peptides with
particle-based systems (Couvreur and Puisieux, 1993).
While encapsulation of peptides and small molecules into
biodegradable microspheres can be achieved using several
techniques and with different polymers, the encapsulation
of proteins still poses major difficulties with respect
to obtaining ‘infusion-like’ or continuous-release profiles
with minimal initial burst and sufficient protein loading
within the microspheres (Kissel et al., 1996; Morlock
et al., 1998).
Drug delivery systems for bone applications have
been mainly focused on 3D porous scaffolds processed
by conventional techniques, which present additional
difficulties, due to the possibility of destroying the
bioactive agent. Some researchers have focused on the
incorporation of microparticles loaded with bioactive
agents into 3D scaffolds, in an attempt to protect the
bioactive agent and still maintain the 3D structure
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of the scaffold, as described by Mikos and co-
•workers, which have added poly(D,L-lactic-co-glycolic AQ4
acid)/poly(ethylene glycol) (PLGA/PEG) microparticles
loaded with the osteogenic peptide TP508 to a mixture
of poly(propylene fumarate) (PPF), poly(propylene
fumarate)–diacrylate (PPF–DA) and sodium chloride
(NaCl), for the fabrication of PPF composite scaffolds
that could allow for tissue ingrowth as well as for
the controlled release of TP508 when implanted in an
orthopaedic defect site (Hedberg et al., 2002). Other
authors have used a 3D chitosan scaffold, which was
combined with transforming TGFβ1-loaded chitosan
microspheres (Lee et al., 2004a).
However, the incorporation of bioactive agents into
µm-sized systems and using them simultaneously as
scaffolds and release systems seems an extremely
interesting alternative. Examples include the use of
dextran-derived materials, which possess hydrophilic
properties and the ability to control drug disso-
lution and permeability. Dextran–glycidylmethacrylate
(Dex–GMA)/poly(ethylene glycol) (PEG) microspheres
with entrapped recombinant human bone morphogenetic
protein-2 (rhBMP-2) showed full preservation of its bio-
logical activity. rhBMP-2 microspheres have good biolog-
ical effects on cultured periodontal ligament cells, and
could achieve a longer action time than concentrations
of rhBMP-2 solution. These properties make those micro-
spheres interesting osteoconductive BMP carriers, allow-
ing the amount of implanted factor required for tissue
regeneration to be decreased (Chen et al., 2005, 2006).
Similarly to BMPs, insulin-like growth factor I (IGF-I)
exerts an important role during skeletal growth and bone
formation. Therefore, its localized delivery appears attrac-
tive for the treatment of bone defects. To prolong IGF-I
delivery, this molecule was entrapped into biodegradable
poly(lactide-co-glycolide) microspheres and the system
evaluated in two defect models of ovine long bones, a
metaphyseal drill hole and a segmental tibia defect. New
bone formation was observed within 3 weeks in the drill
hole and bridging of the segmental defect within 8 weeks.
The authors showed that the IGF-I delivery system down-
regulated inflammatory marker gene expression at the site
of bone injury, induced new bone formation and reduced
bone resorption (Meinel et al., 2001).
Other approaches try to combine further properties
within a single system, such as the one in which in situ
hardening composites are formed, based on an alginate
hydrogel matrix formulated with β-TCP granules and
poly(lactide-co-glycolide) microspheres loaded with the
osteoinductive growth factor insulin-like growth factor
I (IGF-I) (Lee et al., 2004b; Luginbuehl et al., 2005).
This approach combines release properties, structural
support and a ceramic material with osteoconductive
properties for enhanced bone regeneration. Materials
such as collagen–chitosan composite microgranules were
fabricated as bone substitutes for the purpose of obtaining
high bone-forming efficacy. The microgranules have
the flexibility to fill various types of defect sites with
closer packing. The interconnected pores formed spaces
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between the microgranules, which allowed new bone
ingrowth and vascularization. In addition, TGFβ1 was
incorporated into the microgranules in order to improve
bone-healing efficacy. The TGFβ1-loaded microgranules
demonstrated a higher bone regenerative capacity in
rabbit calvarial defects after 4 weeks than the TGFβ1-
unloaded microgranules (Lee et al., 2006).
4. Conclusions
Bone repair has been the subject of intensive research.
Approaches in clinical use aim to regain function, using
materials that replace the damaged tissue rather than
regenerating it. Currently, the approach of research
regarding bone TE is to induce regeneration rather than
just functional repair. Thus, TE can now be simply defined
as the ‘science of persuading the body to heal by its
intrinsic repair mechanisms’ (Agrawal and Ray, 2001).
The complexity of skeletal tissues has been hindering
the development of an effective regeneration system.
Nevertheless, huge steps are being taken regarding the
use of progenitor/stem cells, adequate scaffold materials
and growth factors/bioactive agents. The combination in
a single system of such properties – structural support,
cell support and controlled release – is the way to go, and
materials in the particulate form have all the potential
needed for achieving such a goal.
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